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PERSPECTIVES ON DRUGS 
The EU drugs strategy:  
a model for common action
I  The EU drugs strategy (2013-20) and its action plans
The EU drugs strategy (2013-20) and its two consecutive 
action plans present the framework and priorities of the EU 
and its Member States for addressing  drug policy at European 
level. The strategy promotes a common model with defined 
priorities, objectives, actions and indicators. EU Member 
States, and also some third countries, use this model to 
develop their own policy documents. At the national level, 
drugs strategies are often synchronised with the EU strategy, 
while emphasising different national priorities within the 
overall framework of an integrated, balanced and evidence-
based approach to the drugs problem.
The EU drugs strategy plays an important role in the definition 
of tasks for EU institutions, bodies and agencies in the area 
of drugs. It is also taken into consideration by the European 
Commission when funding priorities are being set in the drugs 
field. The EU drugs strategy aims to add value to Member 
States’ policies by functioning as a platform for coordination 
on tackling issues at international level and promoting the 
EU approach to the drugs problem. It also provides a basis 
for the EU to speak in international fora with a single voice. 
The strategy defines the EU approach to drug policy as being 
integrated and balanced and for the first time evidence based.
The EU drugs strategy 2013-20
The EU drugs strategy 2013-20 is the ninth strategic 
document on illicit drugs endorsed by EU Member States 
since 1990. The strategy, while not legally binding, represents 
the current drug policy position and aspirations of the EU and 
its Member States. It identifies common objectives: to reduce 
the demand for illicit drugs, dependence on illicit drugs and 
On the basis of an external evaluation of 
the EU drugs strategy 2005-12, on  
7 December 2012 the Justice and Home 
Affairs Council of the European Union 
endorsed a new EU drugs strategy  
(2013-20). The strategy was designed 
to be implemented by two consecutive 
4-year action plans. An external evaluation 
of the first action plan (2013-16) was 
completed in 2016 and used to inform the 
drafting of the new action plan  
(2017-20). This analysis takes a look at the 
EU drugs strategy (2013-20), its mid-term 
evaluation and some new elements that 
have been incorporated into the strategy.
U
P
D
A
T
E
D
 1
0
.1
0
.2
0
1
9
emcdda.europa.eu/topics/ 
pods/eu-drugs-strategy-2013-20
Full edition of this article with interactive  
features available online at
PERSPECTIVES ON DRUGS I The EU drugs strategy: a model for common action
related health and social harms, and the supply of illicit drugs. 
For the first time at EU level, Member States have developed 
a common definition of drug demand reduction as being ‘a 
range of equally important and mutually reinforcing measures, 
including prevention (environmental, universal, selective and 
indicated), early detection and intervention, risk and harm 
reduction, treatment, rehabilitation, social reintegration and 
recovery’.
The two consecutive 4-year action plans that translate the 
strategy’s strategic priorities into specific actions were drafted 
in 2013 and 2017 by the then Presidencies of the Council of 
the EU. These plans define a timetable, responsible parties, 
indicators and assessment sources. 
The EU action plan on drugs 2013-16
In June 2013, under the auspices of the Irish Presidency 
of the Council of the EU, Member States adopted a 4-year 
drugs action plan. Like the strategy, the action plan was 
structured around two policy areas, drug demand reduction 
and drug supply reduction, and three cross-cutting themes, 
coordination, international cooperation, and information, 
research, monitoring and evaluation. It contained 16 
objectives and 54 actions designed to enable implementation 
of the strategy. Compared with the previous strategy (2015-
12) and plan (2009-12), the 2013-16 action plan contained 
some new elements. These included the need to address 
the misuse of psychoactive medicines, to develop an EU 
agreement on quality standards in demand reduction, to 
respond to the use of new communication technologies by 
drug traffickers and to promote the role of civil society in EU 
drug policy (see Terms and Concepts). The action plan also 
emphasised the importance of measuring and reporting 
on the implementation of actions and the achievement 
of objectives. For instance, it promoted the continued 
development of indicators in the area of drug supply 
reduction. The action plan set out a range of sources to be 
used as indicators for the actions, including 15 overarching 
indicators based on existing reporting sources, the majority of 
which are maintained by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) and its Reitox network 
of national focal points in the EU Member States. These 
sources facilitated the evaluation of the 2013-16 action plan. 
The mid-term evaluation of the strategy
In 2016, the European Commission launched an external 
evaluation of the EU action plan on drugs (2013-16), which 
also served as a mid-term assessment of the overall drugs 
strategy (RAND Europe, 2016).
The evaluation found that 53 % of actions had been completed 
or were on track, while for 47 % of actions some progress had 
been made but implementation was behind schedule. In the 
area of drug demand reduction, delays were related to the 
objectives on preventing drug use and delaying the onset of 
drug use. In the area of drug supply reduction, the objectives 
to enhance effective law enforcement coordination and 
cooperation and enhance effective judicial cooperation and 
legislation were behind schedule. The evaluation also found 
that some actions needed to be strengthened or new ones 
added to keep up with developing issues and enhance synergy 
with other EU policy areas.
It was also noted that more emphasis should be given to 
addressing the use of new communication technologies in 
illicit drug production and trafficking, as well as the role of 
the internet in drug prevention. Another finding was that 
a new focus was needed to respond to the supply of new 
psychoactive substance and to address the harms associated 
with their use. Increased access to risk and harm reduction 
measures across Member States was also identified as a key 
issue, as was the need for a wider discussion at EU level on 
recent developments in cannabis policy.
The evaluation confirmed that all stakeholders welcomed a 
new drugs action plan. The new plan (2017-20) was adopted 
by the Council of the European Union in 2017 under the 
Maltese Presidency.
The EU action plan on drugs 2017-20
The current action plan includes new actions and addresses 
emerging challenges. In the area of drug demand reduction, a 
stronger focus is placed on ageing drug users and vulnerable 
communities. Equally, attention is also given to risk and 
harm reduction measures, which should play a central role in 
Interactive: world regional strategies available on the EMCDDA website: emcdda.
europa.eu/topics/pods/eu-drugs-strategy-2013-20
I  Interactive element: map
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effective drug policy, including in prison settings. A renewed 
focus is also placed on the misuse of psychoactive medicines.
Building on the achievements of the first action plan in the 
area of supply reduction, the second action plan emphasises 
the need to continue to improve the monitoring of drug supply 
reduction. This involved further building drug supply reduction 
indicators and utilising a range of sources including qualitative 
and contextual information. The current action plan also pays 
particular attention to implementing alternative sanctions for 
drug-using offenders.
In the area of coordination, the new action plan supports the 
development of further opportunities to increase civil society’s 
participation in the formulation, implementation, monitoring 
and evaluation of drugs policies at EU and national levels. At 
international level, the action plan calls for a greater focus on 
enhancing alternative development with other countries.
The new plan also promotes the gathering of evidence on 
potential connections between drug trafficking and the 
financing of terrorist groups and activities; migrant smuggling; 
and trafficking in human beings. A new action is envisaged to 
share knowledge on cannabis legislation at the national and 
international levels.
The final evaluation of the 2013-20 strategy and its 2017-20 
action plan will be conducted by the European Commission in 
2020.
I  New elements of the EU drugs strategy 2013-20 
The EU drugs strategy 2013-20 introduces new concepts to 
EU drug policy.
Harm reduction: the expression ‘harm reduction’ appears 
five times in the 2013-20 strategy, while it was mentioned 
only once in the previous strategy (2005-12). 
Drugs phenomenon: the new drugs strategy refers to a 
‘drugs phenomenon’, while the previous strategy (2005-
12) used the expression ‘drug problem’.
Prison: the 2013-20 strategy calls for equality of care in 
prison settings. The previous strategy did not mention 
prison.
Human rights: for the first time, the drugs strategy 
explicitly promotes respect for human rights in drug policy.
Recovery: the term ‘recovery’ appears for the first time 
in the 2013-20 strategy as an outcome of drug demand 
reduction together with treatment, rehabilitation and 
social reintegration.
Civil society: the 2013-20 strategy foresees the active and 
meaningful participation and involvement of civil society in 
the development and implementation of drug policies, at 
national, EU and international levels. This builds on the call 
for consultation with civil society in the previous strategy.
I  Examples of EU drug policy structures 
Horizontal Working Party on Drugs of the Council of the 
European Union
The Horizontal Working Party on Drugs or Horizontal Drugs 
Group (HDG) was established in 1997 and is responsible for 
leading and managing the Council of the European Union’s 
work on illicit drugs. It is a hub for information exchange 
on national drug policies and drug-related issues among 
EU Member States. It also works with non-EU countries to 
coordinate work being undertaken by the EU and its Member 
States in third countries.
European Parliament Committee on Civil Liberties, Justice 
and Home Affairs
The European Parliament Committee on Civil Liberties, 
Justice and Home Affairs (LIBE Committee) is responsible 
for legislation and policies in the field of Justice and Home 
Affairs (JHA). Along with other JHA agencies, the LIBE 
Committee oversees the work of the EMCDDA. Each year, the 
LIBE Committee gives an opinion on the proposed budget 
for the agency and gives the discharge to the Director for the 
budget of the previous financial year. The LIBE Committee 
elects two independent experts as members on the EMCDDA 
Management Board. Every year, the EMCDDA Director 
presents the European Drug Report and the General Report of 
Activities to the LIBE Committee.
European Commission
The European Commission has many tasks and roles related 
to the illicit drugs area. Among its directorates-general (DGs), 
DG Migration and Home Affairs works on the formulation and 
implementation of policies to prevent and combat serious and 
organised crime. It also works on illicit drug issues generally, 
both within the EU and with third countries and international 
organisations and it is a partner DG to the EMCDDA.
Civil Society Forum on Drugs (CSF)
The Civil Society Forum on Drugs (CSF) is a broad platform 
for a structured dialogue between the Commission and 
European civil society that supports policy formulation and 
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The European Union and its Member States have endorsed 
at the highest political level 11 drugs strategy and action 
plan documents. Looking at these strategies and plans 
demonstrates how the EU approach to drugs has evolved in 
recent decades.  
 
The EU’s drugs strategies and action plans are developed 
through a rigorous process that allows Member States to 
work together on the development of strategic approaches. 
This involves a series of negotiations, evaluations and 
compromises so that consensus can be reached in the form 
of a new strategy document. These strategies present the 
EU model for addressing illicit drug problems within and 
outside the EU. 
 
The EU drugs strategies and plans are based on the 
principles of subsidiarity and proportionality, and on the 
founding values of the European Union. These include 
respect for human dignity, human rights, equality and 
solidarity, and the rule of law. 
 
One new principle has emerged over the years, that of a 
‘balanced approach’. The 1992 action plan recommended 
that future EU action plans on drugs should ‘achieve 
balance’ between demand reduction and law enforcement. 
The 2000-04 plan made a ‘balanced approach’ a strategic 
aim, while the latest strategy (2013-20) includes a 
‘balanced approach’ as a constitutive element of the 
overall EU approach to drugs together with the concepts of 
‘integration’ and an ‘evidence base’. 
 
Over the years, the focus of the EU drugs strategies and 
action plans on the use of indicators and evaluations has 
been developed and refined. Despite the high level at 
which these strategies and action plans operate, there 
has been a desire to identify concrete aims and objectives 
that are measurable and quantifiable. In one sense, the 
general development of an EU approach can be gleaned 
from the move towards a more coordinated approach, 
the culmination of which can, perhaps, be seen as the EU 
speaking with ‘one strong voice in international forums’, as 
stated in the current EU drugs strategy (2013-20). 
The evolution of EU drugs strategies and action plans  
implementation through practical advice. The CSF, whose 
constituency changes every 2 or 3 years with the possibility 
of new candidates, has around 40 members, representing 
various stakeholders and policy options.
